CNTG News and Press, Centogene N.V. From 06/27/22

Centogene (NASDAQ:CNTG) said on Monday it had appointed Miguel Coego Rios as Managing Director and Chief Financial Officer of the Company, effective June 22. Rios joined Centogene as EVP Finance & Legal in February 2022 and served as Interim Chief Financial Officer as of April 1, the...

CAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, June 27, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the commercial-stage, essential biodata life science partner for rare and neurodegenerative diseases, today announced the appointment of Miguel Coego Rios as Managing Dire...

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 27, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the commercial-stage, essential biodata life science partner for rare and neurodegenerative diseases, today announced the voting results of the Company’s Annual General ...

Expanded collaboration to include Phase 3 ACTIVATE-kids and ACTIVATE-kidsT studies CENTOGENE’s genetic testing and Biodatabank identify causative mutations, including the UGT1A1 and PKLR genes, and supports precise diagnosis CAMBRIDGE, Mass. and ROSTOCK, Germany and...

German biotech, Centogene (NASDAQ:CNTG) announced on Wednesday that its CentoCloud cloud-based Software as a Service ((SaaS)) platform for clinical decision making is now CE-marked in Europe under the In Vitro Diagnostics Directive. Europe's new In Vitro Diagnostic Regulation takes effect tom...

CentoCloud, CENTOGENE’s cloud-based Software as a Service (SaaS) platform, is CE-marked under the In Vitro Diagnostics Directive (98/79/EC) CE-marking is required for all in vitro diagnostic (IVD) devices to be placed in the European Economic Area (EEA) countries, as well a...

Newly established WGS recommendations published in the European Journal of Human Genetics Collaborative initiative leverages CENTOGENE’s differentiated diagnostic expertise with testing performed in over 650,000 individuals globally Recommendations provide stand...

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 19, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the commercial-stage essential biodata life science partner for rare and neurodegenerative diseases, today announced that Company management will present in the virtual tra...

Accelerating the path from diagnosis to available treatments for rare metabolic and rare neurodegenerative diseases CENTOGENE and Takeda extend contract to continue providing access to genetic testing for patients with rare metabolic and rare neurodegenerative diseases T...

Image source: The Motley Fool. Centogene N.V. (NASDAQ: CNTG) Q4 2021 Earnings Call Mar 30, 2022 , 8:00 a.m. ET Operator Continue reading For further details see: Centogene N.V. (CNTG) Q4 2021 Earnings Call Transcript